Science Angel Syndicate sources scientific discoveries, conducts due diligence, and helps members invest in scientific companies tackling global challenges.
The funding round was led by the Development Bank of Wales to advance first-in-human studies.
"Vaccination and treatments have reduced the impact of the virus but it is still a significant health risk. Our self-administered and cost-effective antiviral treatment stops the virus from entering and multiplying in the nasal epithelial cells, where it can then spread to the throat and then into the lungs. It is a potential game-changer in the treatment and prevention of coronaviruses, particularly with the emergence of new viruses."
The funding round was led by SFC Capital and OION to prepare the medical device startup for patient trials.
"A younger patient has about a 35% chance of implant failure during their lifetime, and the leading cause of failure is loss of fixation between the bone and the implant"
The pre-seed round was led by Science Angel Syndicate and Fink Family Office to develop cold chain-free vaccine technology.
"Our goal are to make the transportation of vaccines and other life-saving biological materials more efficient and cost-effective while also reducing the carbon footprint of this critical supply chain. We are thrilled to have the support of our investors as we work towards this mission."
The pre-seed round was led by QUBIS Innovation Fund and will support clinical trial preparations and engineering hires.
"We are delighted to have led this investment round into Transdermal Diagnostics. The transdermal approach for glucose monitoring that Transdermal Diagnostics is developing will have a disruptive impact on the diabetes market, we are additionally excited by the company’ potential to expand into the wellness and sports nutrition industries. This funding round alongside the Innovate UK funding will help support them in this journey."
.png)
